EHA 2022: Journaal MM

Het jaarlijkse congres van de European Hematology Association vond dit jaar in plaats in Wenen. In dit EHA-journaal is prof. dr. Sonja Zweegman te gast om samen met Inge Diepman het belangrijkste congresnieuws op het gebied van multipel myeloom door te nemen.

Het nieuws wordt besproken aan de hand van onderstaande EHA-abstracts: 

• Evaluating serum free light chain ratio as a biomarker for multiple myeloma [newly diagnosed MM]
• ATLAS: a phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma
• Phase 3 DETERMINATION trial in newly diagnosed multiple myeloma: lenalidomide, bortezomib and dexamethasone (RVd) ± autologous stem cell transplantation and lenalidomide maintenance to progression 
• RG6234, a novel GPRC5D T-cell engaging bispecific antibody, induces rapid responses in patients with relapsed/refractory multiple myeloma: preliminary results from a first-in-human trial
• Talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in relapsed/refractory multiple myeloma: updated efficacy and safety results from MonumenTAL-1
• Novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results for talquetamab (a GPRC5D x CD3 bispecific antibody) in combination with daratumumab
• Evaluating teclistamab in patients with relapsed/ refractory multiple myeloma following exposure to other B-cell maturation antigen (BCMA)-targeted agents
• Teclistamab in combination with daratumumab, a novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results 
• CARTITUDE-2 cohort B: updated clinical data and biological correlative analyses of ciltacabtagene autoleucel in patients with multiple myeloma and early relapse after initial therapy

Bekijk hier het volledige overzicht van onze EHA 2022 journaals en interviews.